Phase 2 open-label, multicenter clinical study of the safety and efficacy of the intravenous administration of SNS-595 as second-line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC)
Phase of Trial: Phase II
Latest Information Update: 03 Jul 2017
At a glance
- Drugs Vosaroxin (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Sunesis Pharmaceuticals
- 29 Jan 2007 Status changed from recruiting to in progress.
- 23 Dec 2005 New trial record.